STOCK TITAN

Traws Pharma (TRAW) awards COO 93,000 stock options at $0.68 strike

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Traws Pharma, Inc. reported that Chief Operating Officer Nikolay Savchuk received a grant of stock options covering 93,000 shares of common stock on July 9, 2026. The options have an exercise price of $0.68 per share, expire on July 9, 2036, and vest 100% on the first anniversary of the grant date.

Positive

  • None.

Negative

  • None.
Insider Savchuk Nikolay
Role Chief Operating Officer
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 93,000 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 93,000 shares (Direct)
Footnotes (1)
  1. [object Object]
Options Granted 93,000 shares Stock options covering 93,000 shares of common stock granted to COO on July 9, 2026
Exercise Price $0.68 per share Exercise price of stock options granted to COO under 2021 Incentive Compensation Plan
Expiration Date July 9, 2036 Expiration date of the 93,000 stock options granted to COO
Vesting Portion 100% Options vest 100% on the first anniversary of the July 9, 2026 grant date
Post-transaction Options Held 93,000 options Total derivative securities held directly by COO following the grant
Stock Option financial
"Represents stock options awarded by the Issuer's compensation committee"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
Incentive Compensation Plan financial
"under the Issuer's 2021 Incentive Compensation Plan, as amended"
An incentive compensation plan is a formal program that rewards employees and executives with bonuses, stock, or other payments tied to specific performance goals—such as revenue, profit, productivity, or long‑term share price. Investors watch these plans because they shape how leaders make decisions and take risks; like paying a coach by wins rather than effort, well‑designed plans can drive sustainable growth while poor designs can encourage short‑term behaviors that harm shareholder value.
exercise price financial
"conversion_or_exercise_price: "0.6800" for the stock option grant"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest 100% financial
"The stock options under this award will vest 100% on the first anniversary"
expiration date financial
"expiration_date: "2036-07-09" for the granted stock options"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did Traws Pharma (TRAW) disclose for Nikolay Savchuk?

Traws Pharma disclosed that COO Nikolay Savchuk received a grant of 93,000 stock options on July 9, 2026. These options relate to the company’s common stock and were awarded as part of the 2021 Incentive Compensation Plan.

What is the exercise price of the stock options granted to the TRAW COO?

The stock options granted to COO Nikolay Savchuk carry an exercise price of $0.68 per share. This is the price at which he may purchase Traws Pharma common shares when the options become exercisable.

When do Nikolay Savchuk’s Traws Pharma (TRAW) stock options vest?

The stock options awarded to COO Nikolay Savchuk will vest 100% on the first anniversary of the July 9, 2026 grant date. Full vesting means all 93,000 optioned shares become eligible for potential exercise at that time.

What is the expiration date of the Traws Pharma (TRAW) options granted to the COO?

The stock options granted to COO Nikolay Savchuk expire on July 9, 2036. After that date, any unexercised portion of the 93,000 options will lapse and can no longer be used to purchase Traws Pharma common shares.

How many Traws Pharma (TRAW) options does the COO hold after this grant?

Following this award, COO Nikolay Savchuk holds 93,000 stock options directly. This reflects the newly granted options under the company’s 2021 Incentive Compensation Plan, with no additional derivative holdings reported in this disclosure.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Savchuk Nikolay

(Last)(First)(Middle)
C/O TRAWS PHARMA, INC.
12 PENNS TRAIL

(Street)
NEWTOWN PENNSYLVANIA 18940

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Traws Pharma, Inc. [ TRAW ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Operating Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/09/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$0.6807/09/2026A93,00007/09/2027(1)07/09/2036Common Stock93,000$093,000D
Explanation of Responses:
1. Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.
/s/ Nikolay Savchuk07/15/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)